Showing results (81-90 of 121) with videos related to

Sort By:
Pageof 13
International Journal of Radiation Oncology, Biology, Physics|September 7, 2000
A microradiographic investigation of cancellous bone healing after irradiation and hyperbaric oxygenation: a rabbit studyA A Johnsson, M Jacobsson, G Granström, et al.
International Journal of Radiation Biology|November 1, 1989
Fractionation parameters for human tissues and tumorsH D Thames, S M Bentzen, I Turesson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 1, 1990
Time-dose factors in radiotherapy: a review of the human dataH D Thames, S M Bentzen, I Turesson, et al.
Stroke|November 1, 1982
Is occult atrial disorder a frequent cause of non-hemorrhagic stroke? Long-term ECG in 86 patientsN J Abdon, O Zettervall, J Carlson, et al.
Lancet (London, England)|June 27, 1992
Prediction of normal-tissue tolerance to radiotherapy from in-vitro cellular radiation sensitivityN G Burnet, J Nyman, I Turesson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 1, 1994
The relationship between cellular radiation sensitivity and tissue response may provide the basis for individualising radiotherapy schedulesN G Burnet, J Nyman, I Turesson, et al.
European Journal of Haematology|February 1, 1992
Bolus therapy with mitoxantrone and vincristine in combination with high-dose prednisone (NOP-bolus) in resistant multiple myeloma. Nordic Myeloma Study Group (NMSG)F Wisløff, P Gimsing, M Hedenus, et al.
European Journal of Haematology|September 13, 2002
Cytogenetic features of multiple myeloma: impact of gender, age, disease phase, culture time, and cytokine stimulationT Nilsson, S Lenhoff, I Turesson, et al.
British Journal of Haematology|June 3, 1998
Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study groupH Brincker, J Westin, N Abildgaard, et al.
Blood|January 11, 2000
Serum syndecan-1: a new independent prognostic marker in multiple myelomaC Seidel, A Sundan, M Hjorth, et al.
Pageof 13